Fernando Fabio F. P.
- Country
- Spain
- Department
- Oncology
Research Overview
- Comparative Study of JPB898 and Nivolumab in Combination with Ipilimumab for Advanced Unresectable/Metastatic Melanoma
- Efficacy, Safety, and Immunogenicity Comparison of GME751 Versus EU-Authorized Pembrolizumab in Treatment-Naïve Metastatic Non-Small-Cell Lung Cancer Patients
- Evaluation of Safety, Pharmacokinetics, and Preliminary Efficacy of AMX-500 in Patients with Metastatic Castration-Resistant Prostate Cancer
Data & Insights
Has run more than one trial at 285 of 490 partner sites.
Specializations
Haematologic malignancies
Clinical research activity includes acute myeloid leukemia, high-risk myelodysplastic syndromes, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma, and primary central nervous system lymphoma.
- Acute myeloid leukemia
- Myelodysplastic syndromes
- B-cell lymphomas
- Primary central nervous system lymphoma
The portfolio also extends to relapsed and refractory blood cancers, with interest in biomarker-defined subgroups and targeted approaches in leukemia and lymphoma.
Breast cancer and endocrine-driven disease
Research involvement covers hormone receptor-positive breast cancer, HER2-positive breast cancer, HER2-low metastatic breast cancer, triple-negative breast cancer, and early breast cancer, including advanced and metastatic settings.
- Hormone receptor-positive breast cancer
- HER2-positive breast cancer
- Triple-negative breast cancer
- Early breast cancer
Therapeutic interest includes endocrine therapy, CDK4/6 inhibition, and HER2-directed treatment across localized and advanced disease.
Thoracic oncology and lung cancer
Clinical trial activity includes non-small cell lung cancer, small cell lung cancer, EGFR-mutated NSCLC, KRAS G12C-mutated disease, RET fusion-positive NSCLC, and uncommon EGFR mutation subtypes.
- Non-small cell lung cancer
- Small cell lung cancer
- EGFR-mutated NSCLC
- RET fusion-positive NSCLC
The therapeutic landscape also includes advanced and metastatic disease with emphasis on targeted therapy and immunotherapy in lung cancer.
Genitourinary cancers
Research activity spans urothelial carcinoma, bladder cancer, renal cell carcinoma, and prostate cancer, including metastatic and locally advanced presentations.
- Urothelial carcinoma
- Bladder cancer
- Renal cell carcinoma
- Prostate cancer
Areas of therapeutic focus include immune-based treatment, androgen receptor pathway inhibition, and novel antibody-drug conjugates in genitourinary malignancies.
Gastrointestinal, gynecologic, and melanoma oncology
Clinical interests include colorectal cancer, gastric cancer, pancreatic adenocarcinoma, ovarian cancer, endometrial cancer, cervical cancer, and melanoma.
- Colorectal cancer
- Pancreatic adenocarcinoma
- Ovarian cancer
- Melanoma
The therapeutic scope includes gastrointestinal oncology, gynecologic oncology, and cutaneous malignancies, with attention to advanced disease and molecularly selected treatment options.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.